Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Cain

Internal Medicine Charleston, SC Medical Doctor

NPI 1083672745 CMS profile 276046

615 Wesley Drive, Suite 300, Charleston, SC 29407

Open in the dashboard

General payments

$2,251

122 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Cain of Charleston, SC is reported in the CMS Open Payments database as having received $2,251 across 122 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24 1
2024 General $441 21
2023 General $533 27
2022 General $419 25
2021 General $371 21
2020 General $240 15
2019 General $224 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Cain
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Robert Cain were reported at $24. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Robert Cain Internal Medicine median Middle half National median
2019 $224 $159 $48–$570 $163
2020 $240 $119 $33–$402 $114
2021 $371 $135 $37–$521 $132
2022 $419 $141 $42–$496 $149
2023 $533 $149 $45–$519 $160
2024 $441 $154 $47–$537 $164
2025 $24 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $292 17 payments
  2. GlaxoSmithKline, LLC. $208 11 payments
  3. AstraZeneca Pharmaceuticals LP $166 10 payments
  4. Novo Nordisk Inc $157 9 payments
  5. Lilly USA, LLC $135 6 payments
  6. Abbott Laboratories $125 5 payments
  7. Astellas Pharma US Inc $123 7 payments
  8. Exact Sciences Corporation $120 6 payments
  9. Novartis Pharmaceuticals Corporation $111 7 payments
  10. Pfizer Inc. $104 6 payments
  11. Other $709 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,251 122 payments
Products named General payments · program years 2019–2025
  1. Repatha $159 10 payments
  2. EVENITY $132 7 payments
  3. Prolia $132 7 payments
  4. SHINGRIX $124 7 payments
  5. Cologuard Collection Kit $120 6 payments
  6. ENTRESTO $111 7 payments
  7. MYRBETRIQ $108 6 payments
  8. MOUNJARO $98 4 payments
  9. AREXVY $93 5 payments
  10. AIMOVIG $91 6 payments
  11. Other $1,884 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 122 drugs

Part D claims

6,401

Median for Internal Medicine: 777

Drug cost

$411,861

Median for Internal Medicine: $73,373

Branded share of claims

18.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 61 $94,770
Ozempic Semaglutide Brand 64 $74,157
Januvia Sitagliptin Phosphate Brand 47 $50,425
Trulicity Dulaglutide Brand 31 $37,431
Repatha Syringe Evolocumab Brand 14 $22,308
Xarelto Rivaroxaban Brand 14 $10,492
Farxiga Dapagliflozin Propanediol Brand 11 $9,104
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 40 $5,442
Humalog Kwikpen U-100 Insulin Lispro Brand 14 $4,761
Atorvastatin Calcium Generic 373 $4,242

The 10 drugs with the highest cost, of 122 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$134,161

Of which drugs: $49,480

Medicare patients

381

Average age 77

Services billed

2,652

196 women, 185 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 28%
Chronic kidney disease 19%
Cancer 19%
Osteoporosis 19%
Ischemic heart disease 18%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 17 1,260 $25,297
Pcv20 vaccine im 90677 Office 67 67 $19,340
Vaccine for influenza for injection into muscle 90662 Office 58 60 $4,781

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $37
$37 — —
Ozempic
  • Novo Nordisk Inc $32
$32 64 —
GEMTESA
  • Sumitomo Pharma America, Inc. $27
$27 — —
Repatha
  • Amgen Inc. $26
$26 14 —
AREXVY
  • GlaxoSmithKline, LLC. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

122 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record